HLA

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Retrieved on: 
Lunedì, Febbraio 12, 2024
Incidence, Progression-free survival, Co-stimulation, ESMO, HLA, Quality of life, Cancer, Sarcoma, AACR, Stomach, Planegg, Ovarian cancer, Patient, Synovial sarcoma, PD-L1

MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB

Key Points: 
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB
    Planegg/Martinsried, February 12, 2024.
  • Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced the selection of gastric cancer, ovarian cancer and two types of soft tissue sarcomas, myxoid/round cell liposarcoma and synovial sarcoma, as the initial clinical indications for its lead candidate MDG1015.
  • Preclinical data presented in 2023 at the AACR and ESMO conferences demonstrated the clear potential of MDG1015 to improve clinical outcomes in solid tumors.
  • “The selection of these cancers as targets for MDG1015 is an important step as we advance towards the first-in-human trial.

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Retrieved on: 
Mercoledì, Febbraio 7, 2024
Survival, Breast cancer, PFS, Literature, Patient, Pain, TSX, ADC, Therapy, Quality of life, HLA, Spacecraft, Liver disease, Liver, BCT, ILD, Pharmaceutical industry

exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.

Key Points: 
  • exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.
  • Additionally, a disease control rate of 50% was reported in similarly treated evaluable patients who had failed prior antibody-drug conjugate (ADC) therapy.
  • “This data provides further encouragement to us as we continue our pivotal Phase 3 study enrollment.
  • No cases of Interstitial Lung Disease (ILD) with Bria-IMT™ (a well-documented serious side effect of ADCs) reported in this group of patients.

At AGBT, Complete Genomics showcases expanded sequencing applications, talks from customers and collaborators on research powered by the DNBSEQ-T7 Sequencer

Retrieved on: 
Martedì, Febbraio 6, 2024
Genomics, Metagenomics, SAN, Complete Genomics, Research, Mass meeting, CMOS, Environmental monitoring, Chemistry, MPS, HLA, Software, MRD, Standard, Q50, Genome, Antibiotics

SAN JOSE, Calif., Feb. 6, 2024 /PRNewswire/ -- Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, today highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology (AGBT) General Meeting.

Key Points: 
  • After four years in the field, the DNBSEQ-T7, or the T7, remains a leading sequencer in its class, due to its speed, accuracy and flexibility.
  • The T7 enables a wide range of applications such as CompleteWGS, a novel phased genome approach, spatial transcriptomics, cf-DNA sequencing for MRD and early detection, and single cell sequencing.
  • The DNBSEQ™-T20X2 is Complete Genomics' ultra-high-throughput sequencer for the most challenging projects, delivering efficient sequencing at less than $1 per Gigabase.
  • Highly accurate base calling and robust copy number correction is ensured by our robotics-enabled fluidics, which uses whole-wafer-sized slides.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Martedì, Febbraio 6, 2024
TRON, Antigen, DKFZ, Peptide, Research, Heart, Teaching hospital, Map, Patient, H3, Epitope, Ligand, Vaccination, HLA, Doctor of Philosophy, University, Ed Green, Health, Cancer, University Hospital Mannheim, Glioma, Vaccine

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
Martedì, Febbraio 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

Retrieved on: 
Lunedì, Gennaio 22, 2024
Grad, AHRI, Research, CD8, PDC, Epitope, NICD, GMP, Infection, Bill, Immune system, MIT, HLA, Mutation, Human, Safety, Antibody, Harvard University, HIV, Antigen, Mass, CDMO, Vaccine, Ragon Institute, New product development

ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.

Key Points: 
  • ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.
  • The Ragon Institute will lead GRAd-HIV preclinical development.
  • IAVI will be the sponsor and execute a phase I clinical trial to evaluate the safety and immunogenicity of the GRAd-HIV vaccine candidate.
  • Stefano Colloca, ReiThera’s Chief Technology Officer and co-Founder, said,
    “We look forward to collaborating with IAVI and the Ragon Institute and continuing to advance our shared vaccine commitment to address the global challenges posed by HIV.

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Mercoledì, Gennaio 17, 2024
Tumor microenvironment, Development, Death, Pancreatic cancer, Patient, Therapy, Cancer, Neoplasm, DNA, Pancreas, Standard of care, Survival, AMP, Poster, University, Lymphocyte, Risk, HLA, Safety, UCLA, Lymph, CA19-9, Immunization, University of California, PDAC, Research and development, Observation, Biopsy, Colorectal cancer, Nature Medicine, RAS, Pharmaceutical industry

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Gennaio 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Be The Match® Affirms Global Leadership in Life-saving Cell Therapies with New Name, Brand: NMDP℠

Retrieved on: 
Lunedì, Gennaio 8, 2024
NMDP, Marketing, Senior counsel, Ecosystem, Sickle cell disease, University, Physician, National Marrow Donor Program, Student, Research, Bone marrow, HLA, Long Way, MD, Society, Insurance, Volunteering, GVHD, Patient, All, Hematology, Disorder, Pharmaceutical industry

Over nearly four decades, the world has evolved, and so have we, expanding our global footprint, advancing research throughout the cell therapy ecosystem and impacting more people’s lives,” said Amy Ronneberg, CEO, NMDP.

Key Points: 
  • Over nearly four decades, the world has evolved, and so have we, expanding our global footprint, advancing research throughout the cell therapy ecosystem and impacting more people’s lives,” said Amy Ronneberg, CEO, NMDP.
  • Research advancements are driving the organization’s growth in enabling more patients than ever before to access cell therapy – a record 7,435 lives in 2023.
  • “These findings have helped more patients from a diverse range of ethnic backgrounds receive critical cell therapy.
  • Together, NMDP and its network strive to create a world where every patient can receive their life-saving cell therapy.

Diamyd Medical gains market research findings to guide U.S. commercial strategy

Retrieved on: 
Lunedì, Gennaio 8, 2024
Research, USD, Patient, Type 1 diabetes, HLA, Diamyd Medical, Internationalized domain name, Health care, Hospital, Physician, Pharmaceutical industry

"These results both confirm and exceed our previous insights regarding pricing and the market potential of Diamyd in the US", says Ulf Hannelius, CEO of Diamyd Medical.

Key Points: 
  • "These results both confirm and exceed our previous insights regarding pricing and the market potential of Diamyd in the US", says Ulf Hannelius, CEO of Diamyd Medical.
  • Educational Needs and Market Preparation: The research highlighted some gaps in awareness regarding type 1 diabetes staging and the diversity in first-line therapy approaches.
  • These findings underscore the importance of continuous educational efforts in tandem with the introduction of new treatments like Diamyd®.
  • The research pointed to Integrated Delivery Networks (IDNs) as a natural and effective delivery channel for Diamyd® outpatient treatment.